Shares of Epizyme, Inc. (NASDAQ:EPZM) have been given an average recommendation of “Buy” by the thirteen research firms that are presently covering the stock, Marketbeat reports. Two research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $23.14.
Several analysts have recently commented on the stock. HC Wainwright reaffirmed a “buy” rating on shares of Epizyme in a research report on Monday, August 7th. Leerink Swann reaffirmed an “outperform” rating and set a $28.00 price target (down previously from $31.00) on shares of Epizyme in a research report on Wednesday, August 9th. Royal Bank Of Canada reaffirmed a “buy” rating and set a $20.00 price target on shares of Epizyme in a research report on Friday. Cowen and Company reaffirmed a “buy” rating on shares of Epizyme in a research report on Wednesday, June 7th. Finally, BidaskClub raised shares of Epizyme from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 5th.
Shares of Epizyme (NASDAQ:EPZM) opened at 17.20 on Friday. Epizyme has a one year low of $8.38 and a one year high of $18.80. The stock’s market capitalization is $1.01 billion. The stock has a 50 day moving average price of $15.11 and a 200 day moving average price of $15.17.
Epizyme (NASDAQ:EPZM) last released its quarterly earnings results on Friday, August 4th. The biopharmaceutical company reported ($0.48) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.56) by $0.08. The firm had revenue of $10.00 million for the quarter, compared to analyst estimates of $3.95 million. Epizyme had a negative net margin of 1,376.33% and a negative return on equity of 63.10%. The business’s revenue for the quarter was up 2027.7% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.49) EPS. Equities analysts forecast that Epizyme will post ($2.39) earnings per share for the current year.
In other Epizyme news, CFO Andrew E. Singer sold 3,024 shares of the business’s stock in a transaction that occurred on Friday, June 30th. The stock was sold at an average price of $15.50, for a total value of $46,872.00. Following the sale, the chief financial officer now owns 40,529 shares of the company’s stock, valued at $628,199.50. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Peter Tai-Ching Ho sold 15,000 shares of the business’s stock in a transaction that occurred on Monday, June 26th. The shares were sold at an average price of $14.87, for a total value of $223,050.00. Following the completion of the sale, the insider now directly owns 22,228 shares in the company, valued at approximately $330,530.36. The disclosure for this sale can be found here. In the last three months, insiders sold 48,024 shares of company stock worth $706,722. 25.20% of the stock is owned by corporate insiders.
Hedge funds and other institutional investors have recently made changes to their positions in the business. Lord Abbett & CO. LLC purchased a new stake in shares of Epizyme during the second quarter worth $9,726,000. The Manufacturers Life Insurance Company increased its position in shares of Epizyme by 3.3% during the second quarter. The Manufacturers Life Insurance Company now owns 33,137 shares of the biopharmaceutical company’s stock worth $501,000 after acquiring an additional 1,068 shares during the period. State Street Corp increased its position in shares of Epizyme by 59.6% during the second quarter. State Street Corp now owns 1,764,450 shares of the biopharmaceutical company’s stock worth $26,644,000 after acquiring an additional 658,727 shares during the period. Palo Alto Investors LLC increased its position in shares of Epizyme by 18.9% during the second quarter. Palo Alto Investors LLC now owns 5,698,296 shares of the biopharmaceutical company’s stock worth $86,044,000 after acquiring an additional 907,245 shares during the period. Finally, Tudor Investment Corp ET AL purchased a new stake in shares of Epizyme during the second quarter worth $215,000. 83.74% of the stock is currently owned by institutional investors.
Epizyme Company Profile
Epizyme, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company is engaged in the discovery and development of novel epigenetic therapies for cancer patients. The Company develops small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs).
Receive News & Ratings for Epizyme Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme Inc. and related companies with MarketBeat.com's FREE daily email newsletter.